PPCB News & Events

Propanc Biopharma announced it has signed a memorandum of understanding with Avance Clinical. The MOU sets out the shared intent of Propanc and Avance to work together to support the clinical delivery of Propanc's Phase 1b, first-In-human clinical trial for PRP. Importantly, both parties intend to approach the collaboration in a spirit of openness, scientific rigor, and shared problem-solving, with the goal of advancing PRP efficiently from FIH into proof-of-concept and, as data supports, later-phase development. Avance Clinical is a full-service contract research organization headquartered in Australia, with extensive operations across North America, Asia Pacific, New Zealand and Europe.

Propanc Biopharma announced it has initiated a share repurchase program authorizing the company to repurchase a first tranche of up to $500,000 over the next 30-day period.

Propanc Biopharma announced that CEO James Nathanielsz toured a European contract development and manufacturing organization's facility in preparation for the production of the company's lead drug candidate, PRP, ahead of a planned Phase 1b first-in-human clinical study. The schedule developed with the manufacturer includes preproduction in August, an engineering run in October, and active manufacturing starting in December. The company plans to submit a clinical trial application in Australia in 2026 to evaluate the weekly proenzyme therapy in 30 to 40 patients with advanced solid tumors. Nathanielsz said, "Visiting our CDMO partner provides tremendous benefits being able to visualize future cGMP production of PRP, building the foundation for a strong partnership."

Propanc Biopharma announced it has approved a share repurchase program authorizing the company to repurchase up to $5M of its common stock.